TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Wanbury Limited ( (IN:WANBURY) ) has provided an update.
Wanbury Limited announced several key decisions following its Board of Directors meeting on August 4, 2025. The company approved its unaudited financial results for the first quarter ending June 30, 2025, and granted 91,500 stock options to employees under its Employee Stock Option Plan 2016. Additionally, the reappointment of Mr. Chandran Krishnamurthy as a Whole-time Director for a five-year term was approved, pending shareholder approval. Furthermore, Wanbury Limited initiated the closure of three foreign subsidiaries, which had not commenced operations, ensuring no impact on the company’s revenue or business.
More about Wanbury Limited
Wanbury Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of pharmaceutical products. The company is known for its range of formulations and active pharmaceutical ingredients (APIs), catering to various therapeutic segments.
Average Trading Volume: 11,284
Technical Sentiment Signal: Buy
Current Market Cap: 8.87B INR
For an in-depth examination of WANBURY stock, go to TipRanks’ Overview page.